Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript February 21, 2024 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53. Exact Sciences Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.
A $7.5 million grant will support Wisconsin's efforts in becoming a national tech hub focused on the biohealth industry.
Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price objective decreased by analysts at Canaccord Genuity Group from $100.00 to $90.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 50.18% […]
Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.53.